Cost-Utility Analysis of a Latanoprost Cationic Emulsion (STN1013001) versus Other Latanoprost in the Treatment of Open-Angle Glaucoma or Ocular Hypertension and Concomitant Ocular Surface Disease in Germany.
Carlo LazzaroCécile van SteenStephan BilleitHeinrich FrauenknechtChristopher KallenStefan PfennigsdorfUlrich ThelenLuigi AngelilloPublished in: Clinical ophthalmology (Auckland, N.Z.) (2022)
Once on the market, STN1013001 will provide a cost-effective and possibly strongly dominant therapy vs latanoprost for OAG/OHT+OSD patients from a German health system perspective. Future empirical research should confirm these findings.